Agilent Technologies heads into its August 20 earnings date with short sellers retreating sharply and the Street's most influential voice just raising its target — a setup that has shifted decisively from the two-sided tension noted earlier this month.
The most striking development this week is the collapse in short positioning. Short interest fell nearly 25% in a single session on August 11, dropping to 2.0% of the free float — down from around 2.5% the prior day and the lowest level in the 30-day window. That unwind follows a period through late July when shorts had rebuilt from roughly 1.9% to above 2.6% of float. The reversal is sharp and unambiguous: bears who had been adding ahead of earnings are now covering. The borrow market reflects how comfortable that exit has been — availability remains essentially unlimited, with over 233 million shares available to lend and a cost to borrow of just 0.40%. There is no squeeze pressure here; this is voluntary covering, not a forced exit.
Options positioning adds texture to the picture. The put/call ratio ticked up modestly to 0.52 on August 11, fractionally above its recent lows near the 52-week floor of 0.49. Against a 20-day mean of 0.55, the z-score of -0.73 shows call bias remains intact — less extreme than the -1.40 reading from two weeks ago noted in the prior article, but still tilted bullish. The combination of shorts covering and call buyers staying put points to a market that expects a positive earnings outcome rather than bracing for downside.
The Street is moving in the same direction. Morgan Stanley raised its target to $175 this morning — from $160 — while maintaining its Overweight rating. That move is the most aggressive target on record from a bellwether firm in this cycle, and it lands just eight days before the print. The broader analyst community has been steadily ratcheting up: Barclays lifted to $150 in June, BofA to $155, RBC to $155, and Evercore to $148 in early July. The consensus mean target is now $160, against a current price of $149.49 — roughly 7% upside to consensus, though the Morgan Stanley revision implies the Street's high conviction case is closer to 17% above current levels. Bears point to cyclical end-market exposure and China uncertainty; bulls cite the IGNITE transformation driving 200 basis points of pricing improvement and strong biopharma demand.
History gives the earnings setup added weight. The May 27 print moved the stock 17.6% in a single day and 19.4% over the following week — the largest reaction in the dataset. The prior print delivered a more muted 0.8% next-day gain, though that too resolved to a 17.5% five-day move. The stock is already up 7.4% this week and 11.3% over the past month, meaning some of the expected move may already be in the price.
The August 20 print will determine whether the short-covering and call-buying thesis was well-timed or premature — and whether Morgan Stanley's $175 target anchors a new range or proves optimistic.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
